Pharmather talks ketamine as Parkinson's treatment

Executive Summary

• Pharmather Holdings Ltd. outlined its strategy to advance a Phase 3 ketamine program targeting levodopa‑induced dyskinesia (LID‑PD), leveraging a 505(b)(2) regulatory pathway and an FDA‑reviewed CMC package from its ANDA approval.
• The company announced upcoming near‑term milestones, including a pre‑Phase 3 FDA meeting (Q4 2025–Q1 2026), finalization of the pivotal protocol (Q1–Q2 2026), and initiation of the late‑stage study (H1 2026), contingent on regulatory alignment and partnership financing.
• Pharmather highlighted a U.S. market opportunity of $750 million to $2.2 billion, exclusive patent protection through 2036, and active discussions with potential pharmaceutical partners.

Key Details

• Regulatory Pathway: Pursuing a 505(b)(2) route that utilizes existing human data and the FDA‑validated CMC package from the ketamine ANDA to reduce development risk, cost, and timeline.
• Phase 3 Plan: Single, well‑controlled pivotal study designed to support an NDA; primary endpoints focus on dyskinesia reduction, with exploratory assessments of pain and depression.
• Pre‑Phase 3 FDA Interaction: Requesting a meeting in Q4 2025–Q1 2026 to obtain clarity on the Phase 3 design and registrational strategy.
• Clinical Evidence (Phase I/II): Prior study showed 51% reduction in UDysRS scores during infusion 2 (p=0.003), 49% at three weeks (p=0.006), and 41% at three months (p=0.011); no post‑infusion adverse events reported.
• Patent Coverage: U.S. Patent No. 11,426,366 (expires May 2036) covering ketamine for motor disorders, including Parkinson’s disease.
• Market Opportunity: Estimated 1.1 M U.S. Parkinson’s patients; 30‑40% develop LID (330k–440k). Assuming 15‑25% treatment uptake yields 50k–110k patients at $15k‑$20k annual price → addressable market $750 M‑$2.2 B.
• Partnering & Capital Efficiency: Active discussions with prospective pharma partners for acquisition or licensing; aims to fund pivotal development through partnership capital.
• Upcoming Milestones:
• Q4 2025–Q1 2026 – Submit pre‑Phase 3 FDA meeting request, hold meeting, receive minutes.
• Q1–Q2 2026 – Finalize pivotal protocol based on FDA feedback.
• H1 2026 onward – Initiate late‑stage study (subject to regulatory alignment and financing).

Notable Quotes

“This program not only addresses a major unmet need in Parkinson's disease but also highlights the scalability of our 505(b)(2) regulatory strategy,” — Fabio Chianelli, CEO, Pharmather.

“The phase 3‑ready ketamine program for LID‑Parkinson’s positions Pharmather at an inflection point… Our goal is to create meaningful value for both patients and shareholders as we advance toward FDA alignment, pivotal initiation and strategic partnership in 2026.” — Fabio Chianelli, CEO, Pharmather.